Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps
Executive Summary
Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline
You may also be interested in...
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial
Irritable bowel syndrome is a promising, but challenging, U.S. market opportunity. On the one hand it offers a large patient population, which is only modestly served by two prescription therapies, but on the other, FDA sets a high safety bar for approving new IBS therapies because the condition is not seen as life-threatening.
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial
Irritable bowel syndrome is a promising, but challenging, U.S. market opportunity. On the one hand it offers a large patient population, which is only modestly served by two prescription therapies, but on the other, FDA sets a high safety bar for approving new IBS therapies because the condition is not seen as life-threatening.
FDA Reform Bill Will Keep Firms Scrambling To Stay Ahead On Safety Issues
Pharmaceutical companies need to immediately begin assessing whether their drugs are subject to the risk evaluation and mitigation strategies provisions of the FDA Amendments Act, participants were warned during a Food and Drug Law Institute audioconference on the new law, Oct. 4